| Convertible Preferred Stock, Common Stock and Warrants | Dividends on Preferred Stock We immediately recognize
the changes in the redemption value on preferred stock as they occur and the carrying value of the security is adjusted to equal
what the redemption amount would be as if redemption were to occur at the end of the reporting date based on the conditions that
exist as of that date. No dividends were ever declared
by our Board of Directors since our inception on any series of convertible preferred stock. Series D Preferred Stock As of June 30, 2017, and
December 31, 2016, there were 98,105 and 132,489 shares of Series D convertible preferred stock (“Series D Preferred Stock”)
issued and outstanding that are convertible into an aggregate of 1,325,738 and 1,790,392 shares of common stock, respectively. The Series D Preferred Stock
had been issued on March 25, 2015, to certain holders of the Company’s Series A-1 Preferred Stock and Merger warrants (the
“Series A-1 Exchange Securities”) and holders of the Company’s Series B Preferred Stock and Series B warrants
(the “Series B Exchange Securities” and, collectively with the Series A-1 Exchange Securities, the “Exchange
Securities”), all previously issued by the Company. Pursuant to the exchange agreements, the holders exchanged the Exchange
Securities and relinquished any and all other rights they may have had pursuant to the Exchange Securities, their respective governing
agreements and certificates of designation, including any related registration rights, in exchange for an aggregate of 342,906
shares of the Company’s common stock and an aggregate of 238,156 shares of the Company’s newly designated Series D
Preferred Stock, convertible into 3,218,325 shares of common stock. As contemplated by the exchange
agreements and as approved by the Company’s Board of Directors, the Company filed with the Secretary of State of the State
of Delaware a Certificate of Designation of Preferences, Rights and Limitations of Series D Convertible Preferred Stock (the “Series
D Certificate of Designations”), on March 25, 2015. Pursuant to the Series D Certificate of Designations, the Company
designated 1,000,000 shares of its blank check preferred stock as Series D Preferred Stock. Each share of Series D Preferred Stock
has a stated value of $0.01 per share. In the event of a liquidation, dissolution or winding up of the Company, each share
of Series D Preferred Stock will be entitled to a per share preferential payment equal to the stated value. Each share of Series
D Preferred Stock is convertible into 13.5135 shares of common stock. The conversion ratio is subject to adjustment in the
event of stock splits, stock dividends, combination of shares and similar recapitalization transactions. The Company is prohibited
from effecting the conversion of the Series D Preferred Stock to the extent that, as a result of such conversion, the holder beneficially
would own more than 4.99% (provided that certain investors elected to block their beneficial ownership initially at 2.49% in the
Exchange Agreements), in the aggregate, of the issued and outstanding shares of the Company’s common stock calculated immediately
after giving effect to the issuance of shares of common stock upon the conversion of the Series D Preferred Stock. Each share
of Series D Preferred Stock entitles the holder to vote on all matters voted on by holders of common stock. With respect to any
such vote, each share of Series D Preferred Stock entitles the holder to cast such number of votes equal to the number of shares
of common stock such shares of Series D Preferred Stock are convertible into at such time, but not in excess of the beneficial
ownership limitations. Series E Preferred Stock As of June 30, 2017, and
December 31, 2016, there were 33,333 shares of Series E convertible preferred stock (“Series E Preferred Stock”) issued
and outstanding, convertible into 519,751 shares of common stock. On March 30, 2015, the Company
filed with the Secretary of State of the State of Delaware a Certificate of Designation of Preferences, Rights and Limitations
of Series E Convertible Preferred Stock (the “Series E Certificate of Designations”) to designate 100,000 shares of
its blank check preferred stock as Series E Preferred Stock. The shares of Series E Preferred
Stock are convertible into shares of common stock based on a conversion calculation equal to the stated value of such preferred
share, plus all accrued and unpaid dividends, if any, on such share of Series E Preferred Stock, as of such date of determination,
divided by the conversion price. The stated value of each share of Series E Preferred Stock is $75 and the initial conversion price
is $5.55 per share, each subject to adjustment for stock splits, stock dividends, recapitalizations, combinations, subdivisions
or other similar events. In addition, during the period proscribed for in the Series E Certificate of Designations, in the event
the Company issues or sells, or is deemed to issue or sell, shares of common stock at a per share price that is less than the conversion
price then in effect, the conversion price shall be reduced to such lower price, subject to certain exceptions. The Company is
prohibited from effecting a conversion of the share of Series E Preferred Stock to the extent that, as a result of such conversion,
such holder would beneficially own more than 4.99% of the number of shares of common stock outstanding immediately after giving
effect to the issuance of shares of common stock upon conversion of the Series E Preferred Stock, which beneficial ownership limitation
may be increased by the holder up to, but not exceeding, 9.99%. Each holder is entitled to vote on all matters submitted to stockholders
of the Company, and shall have the number of votes equal to the number of shares of common stock issuable upon conversion of such
holder’s share of Series E Preferred Stock, but not in excess of beneficial ownership limitations. The shares of Series E
Preferred Stock bear no interest. On August 22, 2016, when
the Company closed on the August 2016 Public Offering, the current Series E Preferred Stock conversion price of $5.55 per share
was reduced to $4.81 per share under the terms of the Series E Certificate of Designations, resulting in an increase in the number
of shares of common stock to 519,751 that the Series E Preferred Stock may be converted into. There is no further adjustment required
by the Series E Certificate of Designations in the event of an offering of shares below $4.81 per share by the Company. Series F Preferred Stock As of June 30, 2017, and
December 31, 2016, there were 665,281 shares of Series F Preferred Stock, par value of $0.01 per share, issued and outstanding,
convertible into 665,281 shares of common stock. In the event of a liquidation, dissolution or winding up of the Company, each
share of Series F Preferred Stock will be entitled to a per share preferential payment equal to the par value. On August 16, 2016, we filed
a Certificate of Designations, Preferences and Rights of the 0% Series F Convertible Preferred Stock with the Delaware Secretary
of State, designating 1,559,252 shares of preferred stock as 0% Series F Preferred Stock. The shares of Series F Preferred
Stock are convertible into shares of common stock based on a conversion calculation equal to the stated value of such Series F
Preferred Stock, plus all accrued and unpaid dividends, if any, on such Series F Preferred Stock, as of such date of determination,
divided by the conversion price. The stated value of each share of Series F Preferred Stock is $4.81 and the initial conversion
price is $4.81 per share, each subject to adjustment for stock splits, stock dividends, recapitalizations, combinations, subdivisions
or other similar events. In the event of a liquidation, dissolution or winding up of the Company, each share of Series F Preferred
Stock will be entitled to a per share preferential payment equal to the par value. All shares of the Company’s capital stock
will be junior in rank to Series F Preferred Stock with respect to the preferences as to dividends, distributions and payments
upon the liquidation, dissolution and winding-up of the Company, except for the Company’s Series D Preferred Stock and Series
E Preferred Stock. The holders of Series F
Preferred Stock will be entitled to receive dividends if and when declared by our Board of Directors. The Series F Preferred Stock
shall participate on an “as converted” basis, with all dividends declared on the Company’s common stock. In addition,
if we grant, issue or sell any rights to purchase our securities pro rata to all our record holders of our common stock, each holder
will be entitled to acquire such securities applicable to the granted purchase rights as if the holder had held the number of shares
of common stock acquirable upon complete conversion of all Series F Preferred Stock then held. We are prohibited from effecting
a conversion of the Series F Preferred Stock to the extent that, as a result of such conversion, the holder would beneficially
own more than 4.99% of the number of shares of common stock outstanding immediately after giving effect to the issuance of shares
of common stock upon conversion of the Series F Preferred Stock, which beneficial ownership limitation may be increased by the
holder up to, but not exceeding, 9.99%. Each holder is entitled to vote on all matters submitted to stockholders of the Company,
and shall have the number of votes equal to the number of shares of common stock issuable upon conversion of such holder’s
Series F Preferred Stock, but not in excess of the beneficial ownership limitations. Series G Preferred Stock As of June 30, 2017, and
December 31, 2016, there were 1,000,000 and none shares of our Series G Preferred Stock issued and outstanding and convertible
into 1,000,000 and none shares of our common stock, respectively. Pursuant to a Series G Preferred
Stock Certificate of Designations, on May 15, 2017, we designated 5,000,000 shares of our blank check preferred stock as Series
G Preferred Stock, par value of $0.01 per share. The shares of Series G Preferred
Stock are convertible into shares of common stock based on a conversion calculation equal to the stated value of the of such Series
G Preferred Stock, plus all accrued and unpaid dividends, if any, on such Series G Preferred Stock, as of such date of determination,
divided by the conversion price. The stated value of each share of Series G Preferred Stock is $1.75 and the initial conversion
price is $1.75 per share, each subject to adjustment for stock splits, stock dividends, recapitalizations, combinations, subdivisions
or other similar events. The holder of a majority of the Series G Preferred Stock shall have the right to nominate a
candidate for the Board, such right to expire on December 31, 2017. In the event of a liquidation,
dissolution or winding up of the Company, each share of Series G Preferred Stock will be entitled to a per share preferential payment
equal to the par value. All shares our capital stock will be junior in rank to Series
G Preferred Stock with respect to the preferences as to dividends, distributions and payments upon the liquidation, dissolution
and winding-up of the Company, except for the Company’s Series D Convertible Preferred Stock, Series E Convertible Preferred
Stock and Series F Convertible Preferred Stock. We are prohibited from effecting
a conversion of the Series G Preferred Stock to the extent that, as a result of such conversion, the holder would beneficially
own more than 4.99% of the number of shares of common stock outstanding immediately after giving effect to the issuance of shares
of common stock upon conversion of the Series G Preferred Stock, which beneficial ownership limitation may be increased by the
holder up to, but not exceeding, 9.99%. Each holder is entitled to vote on all matters submitted to stockholders of the Company,
and shall have the number of votes equal to the number of shares of common stock issuable upon conversion of such holder’s
Series G Preferred Stock, but not in excess of the beneficial ownership limitations. Series H Preferred Stock As of June 30, 2017, and
December 31, 2016, there were 850 and none shares of our Series H Preferred Stock issued and outstanding and convertible into 485,714
and none shares of our common stock, respectively. Pursuant to a Series H Preferred
Stock Certificate of Designations, on May 3, 2017, we designated 2,000 shares of our blank check preferred stock as Series H Preferred
Stock, par value of $0.01 per share. The shares of Series H Preferred
Stock are convertible into shares of common stock based on a conversion calculation equal to the stated value of the Series H Preferred
Stock, plus the Base Amount, if any, on such Series H Preferred Stock, as of such date of determination, divided by the conversion
price. The stated value of each share of Series H Preferred Stock is $1,000 and the initial conversion price is $1.75 per share,
each subject to adjustment for stock splits, stock dividends, recapitalizations, combinations, subdivisions or other similar events. In the event of a liquidation,
dissolution or winding up of the Company, each share of Series H Preferred Stock will be entitled to a per share preferential payment
equal to the Base Amount. All shares of our capital stock will be junior in rank to
Series H Preferred Stock with respect to the preferences as to dividends, distributions and payments upon the liquidation, dissolution
and winding-up of the Company other than Series A through G Preferred Stock. We are prohibited from effecting
a conversion of the Series H Preferred Stock to the extent that, as a result of such conversion, the holder would beneficially
own more than 4.99% of the number of shares of common stock outstanding immediately after giving effect to the issuance of shares
of common stock upon conversion of the Series H Preferred Stock, which beneficial ownership limitation may be increased by the
holder up to, but not exceeding, 9.99%. Each holder is entitled to vote on all matters submitted to stockholders of the Company,
and shall have the number of votes equal to the number of shares of common stock issuable upon conversion of such holder’s
Series H Preferred Stock, but not in excess of the beneficial ownership limitations. Series I Preferred Stock As of June 30, 2017, and
December 31, 2016, there were 1,968,664 and none shares of our Series I convertible preferred stock (the “Series I Preferred
Stock”) issued and outstanding and convertible into 1,968,664 and none shares of our common stock, respectively. Pursuant to a Series I Preferred
Stock Certificate of Designations, on May 26, 2017, we designated 1,968,664 shares of our blank check preferred stock as Series
I Preferred Stock, par value of $0.01 per share. Each share of Series
I Preferred Stock has a stated value of $0.01 per share. In the event of a liquidation, dissolution or winding up of the Company,
each share of Series I Preferred Stock will be entitled to a per share preferential payment equal to the stated value. Each share
of Series I Preferred Stock is convertible into one share of common stock. The conversion ratio is subject to adjustment in
the event of stock splits, stock dividends, combination of shares and similar recapitalization transactions. The Company is
prohibited from effecting the conversion of the Series I Preferred Stock to the extent that, as a result of such conversion, the
holder beneficially owns more than 4.99%, in the aggregate, of the issued and outstanding shares of the Company’s Common
Stock calculated immediately after giving effect to the issuance of shares of Common Stock upon the conversion of the Series I
Preferred Stock (the “Beneficial Ownership Limitation”), which beneficial ownership limitation may be increased by
the holder up to, but not exceeding, 9.99%. Each share of Series I Preferred Stock entitles the holder to vote on all matters
voted on by holders of Common Stock. With respect to any such vote, each share of Series I Preferred Stock entitles the holder
to cast such number of votes equal to the number of shares of Common Stock such shares of Series I Preferred Stock are convertible
into at such time, but not in excess of the Beneficial Ownership Limitation. Warrants Issued in Connection with April 2015 Private Placement As of June 30, 2017, and
December 31, 2016, there were warrants to purchase 706,262 shares at $11.10 per share and 99,099 shares at $2.00 per share; and
as of December 31, 2016, there were warrants to purchase 805,361 shares of common stock at $11.10 per share that were outstanding
that were remaining from our private offering in March and April 2015 (the “April 2015 Private Placement”) in which
we sold $8,546,348 worth of units (the “Units”), net of $668,150 in issuance costs, of which $2,500,000 of the Units
consisted of Series E Preferred Stock and the balance consisted of 1,660,271 shares of common stock, together with warrants to
all investors to purchase 1,055,361 shares of common stock at $11.10 per share. Each Unit was sold at a purchase price
of $5.55 per Unit. OPKO Health, Inc., the lead investor in the April 2015 Private Placement, purchased $2,500,000 worth of Units
consisting of all of the shares of the Series E Preferred Stock. The warrants are exercisable
upon issuance and expire October 10, 2017, and may be exercised for cash or on a cashless basis if at $11.10 per share, or for
cash if at $2.00 per share. The warrant exercise price is subject to certain adjustments including stock splits, dividends and
reverse-splits. The Company is prohibited from effecting the exercise of the warrants to the extent that, as a result of such exercise,
the holder beneficially would own more than 4.99% in the aggregate, of the issued and outstanding shares of the Company’s
common stock calculated immediately after giving effect to the issuance of shares of common stock upon the exercise of the warrants.
Investor rights of participation in future financings by the Company expired on April 10, 2017. The warrants are not listed on
any securities exchange or other trading market. In connection with the May
2017 Public Offering, for the investors in the April 2015 Private Placement to issue 2,900,000 shares of common stock (the “Inducement
Shares”), they were required to invest at least 25% of their original investment from such private financing in the May 2017
Public Offering and still hold 100% of their common stock or Series E preferred stock from the private 2015 financing, and must
also must agree to amend the terms of their outstanding warrants that had an exercise price of $11.10 per share, such that the
amended warrants shall have an exercise price of $2.00 per share and no cashless exercise feature (as amended, the “Inducement
Amended Warrants”). The Company further agreed with the lead investor in the May 2017 Public Offering (the “Lead Investor”)
in connection with the warrant issued in the April 2015 Private Placement to register for resale on a registration statement all
the Inducement Shares and shares of common stock underlying the Inducement Amended Warrants. Warrants Issued in Connection with October
2015 Public Offering As of June 30, 2017, and
December 31, 2016, there were warrants to purchase 168,919 shares of common stock that were outstanding that we issued in connection
with our public offering on October 5, 2015, which consisted of 337,838 shares of common stock and warrants to purchase 168,919
shares of common stock, at an offering price of $8.14 per share. For every two shares of common stock sold, the Company issued
one warrant to purchase one share of common stock. We received $2,750,000 in gross proceeds, before underwriting discounts
and commissions and offering expenses totaling approximately $586,608. The shares and warrants were separately issued and sold
in equal proportions. The warrants are immediately exercisable, expire September 30, 2018, and have an exercise price of $9.77
per share. The warrants are not listed on any securities exchange or other trading market. August 2016 Public Offering On August 22, 2016, we closed
a public offering of 1,297,038 shares of common stock and 665,281 shares of Series F preferred stock, and warrants to purchase
1,962,319 shares of common stock at $5.55 per share and warrants to purchase 1,962,319 shares of common stock at $6.29 per share,
at an offering price of $4.81 per share. For every one share of common stock or Series F preferred stock sold, we issued
one warrant to purchase one share of common stock at $5.55 per share and one warrant to purchase one share of common stock at $6.29
per share. We received $9,438,753 in gross proceeds, before underwriting discounts and commissions and offering expenses
totaling $871,305. The gross proceeds include the underwriter’s over-allotment option, which it exercised on the closing
date. May 2017 Private Placement On May 3, 2017, we entered
into separate subscription agreements with accredited investors pursuant to which we sold an aggregate of $850,000, or 850 shares,
of Series H Preferred Stock, . In the event of a liquidation,
dissolution or winding up of the Company, each share of Series H Preferred Stock will be entitled to a per share preferential payment
equal to the Base Amount. All shares of our capital stock will be junior in rank to Series
H Preferred Stock with respect to the preferences as to dividends, distributions and payments upon the liquidation, dissolution
and winding-up of the Company other than Series A through G Preferred Stock. We are prohibited from effecting
a conversion of the Series H Preferred Stock to the extent that, as a result of such conversion, the holder would beneficially
own more than 4.99% of the number of shares of common stock outstanding immediately after giving effect to the issuance of shares
of common stock upon conversion of the Series H Preferred Stock, which beneficial ownership limitation may be increased by the
holder up to, but not exceeding, 9.99%. Each holder is entitled to vote on all matters submitted to stockholders of the Company,
and shall have the number of votes equal to the number of shares of common stock issuable upon conversion of such holder’s
Series H Preferred Stock, but not in excess of the beneficial ownership limitations. The shares were offered
and sold solely to “accredited investors” in reliance on the exemption from registration afforded by Rule 506 of Regulation
D and Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). On the closing date, we entered
into registration rights agreements with each of the investors, pursuant to which we agreed to undertake to file a registration
statement to register the resale of the shares within thirty (30) days following the closing date, to cause such registration statement
to be declared effective by the Securities and Exchange Commission within sixty (60) days of the closing date and to maintain the
effectiveness of the registration statement until all of such shares have been sold or are otherwise able to be sold pursuant to
Rule 144 under the Securities Act, without any restrictions. On May 10, 2017, we entered
into exchange agreements (the “Exchange Agreements”) with each of the holders of our Series H Preferred Stock representing
an aggregate of $850,000 of our Series H Preferred Stock (the “Exchange Securities”) with such exchange to be effective
on the closing of our May 2017 Public Offering. Prior to the closing of the May 2017 Public Offering, we and the holders rescinded
and cancelled the Exchange Agreements and they have no force and effect and no transaction contemplated by the Exchange Agreements
was consummated. May 2017 Public Offering On May 19, 2017, we closed
a public offering of 1,342,858 shares of common stock and 1,000,000 shares of newly designated 0% Series G Convertible Preferred
Stock, or Series G Preferred Stock, at $1.75 per share of common stock and Series G Preferred Stock, or the May 2017 Public Offering.
The Series G Preferred Stock is initially convertible into 1,000,000 shares of common stock, subject to adjustment for stock
splits, stock dividends, recapitalizations, combinations, subdivisions or other similar events and was purchased by certain existing
investors of the Company who, as a result of their purchases of common stock, would hold in excess of 4.99% of our issued and outstanding
common stock. We received $4,100,000 in gross proceeds, before underwriting discounts and commissions and offering expenses totaling
$397,743. The May 2017 Public Offering
was consummated pursuant to an underwriting agreement that we signed on May 15, 2017, with Laidlaw & Company (UK) Ltd. (“Laidlaw”),
as underwriter (the “Underwriter”) pursuant to which, among other things, we agreed to issue and sell to the Underwriter,
and the Underwriter agreed to purchase from us, in an underwritten public offering, an aggregate of 1,342,858 shares of common
stock and 1,000,000 shares of Series G Preferred Stock. We granted the Underwriters an option for a period of up to 45 days from
the date of our prospectus to purchase up to an aggregate of 201,428 additional shares of our common stock at the public offering
price of $1.75 per share, less the underwriting discount, solely to cover overallotments, which was not exercised. In connection with the May
2017 Public Offering, we agreed with the lead investor of the August 2016 Public Offering (the “August Lead Investor”)
pursuant to a Letter Agreement, dated May 18, 2017, to issue the Inducement Shares to the investors in the August 2016 Public Offering
(the “August 2016 Investors”), as incentive shares to those investors to make a minimum required investment in this
public offering of at least 50% of their investment in the $9.4 million August 2016 Public Offering, or the Minimum Required Investment,
and who still hold 100% of the shares of common stock previously acquired. Such August 2016 Investors shall be entitled to receive
their pro rata share of 2,900,000 shares, after the Lead Investor in this offering receives the first 10%. For the August 2016
Investors who purchased Series F Preferred Stock and made the Minimum Required Investment and who still held 100% of the shares
of Series F Preferred Stock at the closing of the May 2017 Public Offering, they may, instead of receiving a pro rata share of
the 2,610,000 shares remaining after the August Lead Investor receives the first 290,000 shares, elect to receive their Inducement
Shares in the form of a new Series I Preferred Stock to be created with similar rights as currently exist in the Series G Preferred
Stock. The stated value of each share of Series I Preferred Stock will be $0.01 and the conversion rate shall be one (1) share
of common stock for one (1) share of Series I Preferred Stock, each subject to adjustment for stock splits, stock dividends, recapitalizations,
combinations, subdivisions or other similar events. In the event of a liquidation, dissolution or winding up of the Company, each
share of Series I Preferred Stock will be entitled to a per share preferential payment equal to the par value, or $0.01 per share.
All shares of the Company’s capital stock will be junior in rank to the Series I Preferred Stock at the time of creation,
with respect to the preferences as to dividends, distributions and payments upon the liquidation, dissolution and winding-up of
the Company, except for the Company’s Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series
G Preferred Stock, and Series H Preferred Stock. Also in connection with
the May 2017 Public Offering, for these August 2016 Investors to receive the Inducement Shares, each of them must also agree to
the cancellation of the warrants issued to them in the August 2016 Public Offering. Investors in the Company’s 2015 private
offering that invest at least 25% of their original investment from such private financing in the May 2017 Public Offering and
still hold 100% of their common stock or Series E preferred stock from the private 2015 financing also must agree to amend the
terms of their outstanding warrants that currently have an exercise price of $11.10 per share, such that the amended warrants shall
have an exercise price of $2.00 per share and no cashless exercise feature (as amended, the “Inducement Amended Warrants”).
The Company agreed with the Lead Investor to register for resale on a registration statement all the Inducement Shares and shares
of common stock underlying the Inducement Amended Warrants, and to issue the Inducement Shares to each investor meeting the investment
and ownership terms described above. Based on the closing of
the Offering, and election of certain prior investors who made the Minimum Required Investment and elected to take Series I Preferred
Stock upon its creation, 931,336 Inducement Shares of common stock were issued and 1,968,664 Inducement Shares were issued in the
form of Series I Preferred Stock that was created following the closing of the May 2017 Public Offering and issued following verification
with each investors that the terms of the Inducement Shares have been met. The Company recorded a deemed dividend of $5,220,000
for the three and six months ended June 30, 2017 in connection with issuing the Inducement Shares. Additionally, in connection
with participation by the April 2015 investors in the May 2017 Public Offering, the Company revised the exercise price for 90,099
warrants from $11.10 to $2.00 per warrant share and recorded a deemed dividend of $19.413 for the three and six months ended June
30, 2017. May 2017 Letter Agreement As a condition to the Lead
Investor leading an investment in the May 2017 Public Offering, including the requirement that we offer incentive shares to August
2016 Investors who participate in making the Minimum Required Investment in the May 2017 Public Offering, we agreed to the following:
Board Nomination The Company shall nominate one candidate to the Board of Directors of the Company acceptable to the holder of a majority of the Series G Preferred Stock by December 31, 2017, and two current Board members will resign.
Executive Hire The Company shall hire a new C-level executive in a leadership role by July 15, 2017.
Board Compensation The Company is obligated to issue an aggregate of 1,050,000 options to certain employees and members of the Board, at a price not less than $2.00 per share, and 50,000 options to each other Board member at the current market price in connection with this offering. The options shall be issued pursuant to the Company’s option plan and are subject to the requisite approvals and subject to availability under the plan. To the extent we need to increase the number of shares available under such plan, we will need the approval of our Board and Stockholders. All Board fees will be waived for 2017.
Funds Held in Escrow $500,000 of the funds from this offering will be held in escrow and released to one or more investor relations services acceptable to the Company following the closing of this offering. Additionally we granted
the Lead Investor in the May 2017 Public Offering certain rights to approve future (i) issuances of our securities, (ii) equity
or debt financings and (iii) sales of any development product assets currently held by us, subject to certain exceptions, if such
securities are sold at price below $2.50 per share and for as long as the Lead Investor in the offering holds 50% or more of the
shares of Series G Preferred Stock purchased by the Lead Investor in this offering (the “May 2017 Consent Right”).
All other prior consent rights of the Lead Investor have been superseded by the May 2017 Consent Right. For the period from
the May 2017 Public Offering to June 30, 2017, the Company incurred approximately $177,000 in expenses related to outside
investor relations services. Further, two Board members have resigned, which achieves one of the conditions of the Lead
Investor. Consultant Grants On January 13, 2016, the
Board of Directors approved the issuance of 13,514 shares of restricted stock with immediate vesting valued at $64,000 to a consultant
for advisory services to the Company. On February 10, 2017, the
Company entered into a consulting agreement with MDM Worldwide, pursuant to which MDM Worldwide shall provide investor relations
services to the Company in consideration for an immediate grant of 20,000 shares of the Company’s common stock and a monthly
cash retainer of $10,000 a month for ongoing services for a period of one year. As the sh |
